欧盟 - 德文 - EMA (European Medicines Agency)

bristol-myers squibb pharma eeig - ozanimod hydrochloride - multiple sclerosis, relapsing-remitting; colitis, ulcerative - immunsuppressiva - multiple sclerosiszeposia is indicated for the treatment of adult patients with relapsing remitting multiple sclerosis (rrms) with active disease as defined by clinical or imaging features. ulcerative colitiszeposia is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis (uc) who have had an inadequate response, lost response, or were intolerant to either conventional therapy or a biologic agent.

欧盟 - 德文 - EMA (European Medicines Agency)

bristol myers squibb pharma eeig - luspatercept - anemia; myelodysplastic syndromes; beta-thalassemia - andere antianemic vorbereitungen - reblozyl is indicated for the treatment of adult patients with transfusion-dependent anaemia due to very low, low and intermediate-risk myelodysplastic syndromes (mds) with ring sideroblasts, who had an unsatisfactory response to or are ineligible for erythropoietin-based therapy (see section 5. reblozyl is indicated in adults for the treatment of anaemia associated with transfusion dependent and non transfusion dependent beta thalassaemia (see section 5.

欧盟 - 德文 - EMA (European Medicines Agency)

bristol myers squibb pharma eeig - fedratinib dihydrochloride monohydrate - myeloproliferative disorders; primary myelofibrosis - antineoplastische mittel - inrebic is indicated for the treatment of disease-related splenomegaly or symptoms in adult patients with primary myelofibrosis, post polycythaemia vera myelofibrosis or post essential thrombocythaemia myelofibrosis who are janus associated kinase (jak) inhibitor naïve or have been treated with ruxolitinib.

欧盟 - 德文 - EMA (European Medicines Agency)

bristol-myers squibb pharma eeig - azacitidin - leukämie, myeloisch, akut - antineoplastische mittel - onureg is indicated as maintenance therapy in adult patients with acute myeloid leukaemia (aml) who achieved complete remission (cr) or complete remission with incomplete blood count recovery (cri) following induction therapy with or without consolidation treatment and who are not candidates for, including those who choose not to proceed to, hematopoietic stem cell transplantation (hsct).

欧盟 - 德文 - EMA (European Medicines Agency)

bristol-myers squibb pharma eeig - idecabtagene vicleucel - multiple myeloma; neoplasms; cancer; neoplasms, plasma cell; hemostatic disorders; vascular diseases; cardiovascular diseases; paraproteinemias; blood protein disorders; hematologic diseases; hemic and lymphatic diseases; hemorrhagic disorders; infectious mononucleosis; lymphoproliferative disorders; immunoproliferative disorders; immune system diseases - antineoplastische mittel - abecma is indicated for the treatment of adult patients with relapsed and refractory multiple myeloma who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor and an anti cd38 antibody and have demonstrated disease progression on the last therapy.

欧盟 - 德文 - EMA (European Medicines Agency)

bristol-myers squibb pharma eeig - cd19-directed genetically modified autologous cell-based product consisting of purified cd8+ t-cells (cd8+ cells), cd19-directed genetically modified autologous cell-based product consisting of purified cd4+ t cells (cd4+ cells) - lymphoma, large b-cell, diffuse; lymphoma, follicular; mediastinal neoplasms - antineoplastische mittel - breyanzi is indicated for the treatment of adult patients with diffuse large b-cell lymphoma (dlbcl), high grade b-cell lymphoma (hgbcl), primary mediastinal large b-cell lymphoma (pmbcl) and follicular lymphoma grade 3b (fl3b), who relapsed within 12 months from completion of, or are refractory to, first-line chemoimmunotherapy.

瑞士 - 德文 - Swissmedic (Swiss Agency for Therapeutic Products)

bristol-myers squibb sa - pomalidomidum - hartkapseln - pomalidomidum 1 mg, mannitolum, amylum pregelificatum, natrii stearylis fumaras corresp. natrium 0.018 mg, kapselhülle: gelatina, e 171, e 132, e 172 (flavum), drucktinte: lacca, e 171, simeticonum, propylenglycolum, ammoniae solutio 28 per centum, drucktinte: lacca, e 172 (nigrum), propylenglycolum, ammoniae solutio 28 per centum, pro capsula. - behandlung des multiplen myeloms - synthetika

瑞士 - 德文 - Swissmedic (Swiss Agency for Therapeutic Products)

bristol-myers squibb sa - pomalidomidum - hartkapseln - pomalidomidum 2 mg, mannitolum, amylum pregelificatum, natrii stearylis fumaras corresp. natrium 0.036 mg, kapselhülle: gelatina, e 171, e 132, e 127, e 172 (flavum), drucktinte: lacca, e 171, simeticonum, propylenglycolum, ammoniae solutio 28 per centum, pro capsula. - behandlung des multiplen myeloms - synthetika

瑞士 - 德文 - Swissmedic (Swiss Agency for Therapeutic Products)

bristol-myers squibb sa - pomalidomidum - hartkapseln - pomalidomidum 3 mg, mannitolum, amylum pregelificatum, natrii stearylis fumaras corresp. natrium 0.025 mg, kapselhülle: gelatina, e 171, e 132, e 172 (flavum), drucktinte: lacca, e 171, simeticonum, propylenglycolum, ammoniae solutio 28 per centum, pro capsula. - behandlung des multiplen myeloms - synthetika

瑞士 - 德文 - Swissmedic (Swiss Agency for Therapeutic Products)

bristol-myers squibb sa - pomalidomidum - hartkapseln - pomalidomidum 4 mg, mannitolum, amylum pregelificatum natrii stearylis fumaras corresp. natrium 0.033 mg, kapselhülle: gelatina, e 171, e 132, e 133, drucktinte: lacca, e 171, simeticonum, propylenglycolum, ammoniae solutio 28 per centum, pro capsula. - behandlung des multiplen myeloms - synthetika